m-THPC-mediated photodynamic therapy (PDT) does not induce resistance to chemotherapy, radiotherapy or PDT on human breast cancer cells in vitro.
Photodynamic therapy (PDT) uses laser light to activate a photosensitizer that has been absorbed preferentially by cancer cells after systemic administration. A phototoxic reaction ensues resulting in cell death and tissue necrosis. Some cells, however, may survive PDT. This study was performed to determine if surviving human breast cancer cells (MCF-7) can become resistant to PDT, chemotherapy or radiotherapy. The MCF-7 cells were cultured under standard conditions prior to being exposed to the photosensitizer, 5,10,15,20-meta-tetra(hydroxyphenyl)chlorin (m-THPC), for 24 h and then irradiated with laser light (652 nm). Surviving cells were allowed to regrow by allowing a 2 week interval between each additional PDT. After the third and final treatment, colony formation assays were used to evaluate the sensitivity of cultured cells to ionizing radiation and PDT and the ATP cell viability assay tested in vitro chemosensitivity. Flow cytometry was used to analyze the cell cycle. No alterations in the cell cycle were observed after three cycles of PDT with m-THPC. Similar responses to chemotherapy and ionizing radiation were seen in control and treatment groups. The m-THPC-sensitized PDT did not induce resistance to subsequent cycles of PDT, chemo- or radiotherapy. Photodynamic therapy with m-THPC may represent a novel adjunctive treatment of breast cancer that may be combined with surgery, chemotherapy or ionizing radiation.
Hornung
R
R
Department of Gynecology and Obstetrics, University Hospital, Zurich, Switzerland.
Walt
H
H
Crompton
N E
NE
Keefe
K A
KA
Jentsch
B
B
Perewusnyk
G
G
Haller
U
U
Köchli
O R
OR
D000970:Antineoplastic Agents / Q000097:blood / Q000627:therapeutic use / Q000633:toxicity*; D001943:Breast Neoplasms; D002470:Cell Survival / Q000187:drug effects* / Q000528:radiation effects; D019008:Drug Resistance, Neoplasm / Q000528:radiation effects; D005260:Female; D006801:Humans; D008652:Mesoporphyrins / Q000633:toxicity*; D009336:Necrosis; D017239:Paclitaxel / Q000633:toxicity; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000633:toxicity*; D011836:Radiation Tolerance; D011878:Radiotherapy; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents; D008652:Mesoporphyrins; D017319:Photosensitizing Agents; C072269:temoporfin; D017239:Paclitaxel